HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
Opus Genetics, Inc.
Opus Genetics, Inc. IRD | 0.00 |
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:
IRD) with a Buy and maintains $8 price target.
